Nanocargos: A Burgeoning Quest in Cancer Management

Author(s): Atul Jain, Teenu Sharma, Sumant Saini, Om Prakash Katare, Vandana. Soni, Bhupinder Singh*

Journal Name: Current Nanomedicine
Formerly Recent Patents on Nanomedicine

Volume 10 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Cancer, a complex series of diseased conditions, contributes to a significant health problem and is a leading cause of mortalities across the world. Lately, with the advent of improved diagnostics and imaging techniques, and newer advanced oral chemotherapeutics; millions of cancer affected people can lengthen their life span. Despite all the challenges associated with an active chemotherapeutic molecule like microenvironment and the intestinal barrier of the gastrointestinal tract (GIT) etc., the oral delivery remains the most acceptable route of drug administration. In this regard, nanotechnology has played a significant role in the counteracting the challenges encountered with newly developed molecules and aiding in improving their bioavailability and targetability to the tumour site, while administering through the oral route. Several literature instances document the usage of nanostructured drug delivery systems such as lipid-based, polymerbased or metallic nanomaterials to improve the efficacy of chemotherapy. Besides, sitespecific targeted surface-modified drug delivery system designed to deliver the active molecule has opened up to the newer avenues of nanotechnology. However, the issue of potential toxicity allied with nanotechnology cannot be compromised and thus, needs specific ethical regulations and guidelines. The various in vitro models have been developed to evaluate the in vitro toxicity profile which can be further correlated with the invivo model. Thus, this review provides a summarized account of the various aspects related to the role of nanotechnology in cancer therapy and various related issues thereof; that must be triumphed over to apprehend its full promise.

Keywords: Cancer, oral delivery, nanotechnology, polymer-based, lipid-based, in vitro model.

[1]
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62(4): 220-41.
[http://dx.doi.org/10.3322/caac.21149] [PMID: 22700443]
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5-29.
[http://dx.doi.org/10.3322/caac.21254] [PMID: 25559415]
[3]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[4]
Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005; 44(1): 68-97.
[http://dx.doi.org/10.1016/j.plipres.2004.12.001] [PMID: 15748655]
[5]
Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine (Lond) 2012; 8(2): 147-66.
[http://dx.doi.org/10.1016/j.nano.2011.05.016] [PMID: 21703993]
[6]
Ravichandran R. Nanotechnology-based drug delivery systems. Nanobiotechnol 2009; 5: 17-33.
[http://dx.doi.org/10.1007/s12030-009-9028-2]
[7]
Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010; 62(2): 90-9.
[http://dx.doi.org/10.1016/j.phrs.2010.03.005] [PMID: 20380880]
[8]
Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009; 30(11): 592-9.
[http://dx.doi.org/10.1016/j.tips.2009.08.004] [PMID: 19837467]
[9]
Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1974; 1(7870): 1313-6.
[http://dx.doi.org/10.1016/S0140-6736(74)90682-5] [PMID: 4134296]
[10]
Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 2000; 3(3): 171-7.
[http://dx.doi.org/10.1054/drup.2000.0138] [PMID: 11498382]
[11]
Noble OC, Kirpotin BD, et al. Development of ligand targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004; 8(4): 335-53.
[PMID: 15268628]
[12]
Weinstein JN, Leserman LD. Liposomes as drug carriers in cancer chemotherapy. Pharmacol Ther 1984; 24(2): 207-33.
[http://dx.doi.org/10.1016/0163-7258(84)90035-4] [PMID: 6379684]
[13]
Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36(5): 1177-87.
[http://dx.doi.org/10.1016/S0360-3016(96)00389-6] [PMID: 8985041]
[14]
Chelvi TP, Ralhan R. Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy. Int J Hyperthermia 1995; 11(5): 685-95.
[http://dx.doi.org/10.3109/02656739509022500] [PMID: 7594819]
[15]
Zheng Y, Fu F, Zhang M, Shen M, Zhub M, Shi X. Med. Multifunctional dendrimers modified with alphatocopheryl succinate for targeted cancer therapy. Chem Commun (Camb) 2014; 5: 833-98.
[16]
Yuyama Y, Tsujimoto M, Fujimoto Y, Oku N. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. Cancer Lett 2000; 155(1): 71-7.
[http://dx.doi.org/10.1016/S0304-3835(00)00410-9] [PMID: 10814882]
[17]
Kawai N, Ito A, Nakahara Y, et al. Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate 2006; 66(7): 718-27.
[http://dx.doi.org/10.1002/pros.20394] [PMID: 16425185]
[18]
Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007; 13(9): 2722-7.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2443] [PMID: 17473205]
[19]
Wang S, Low PS. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release 1998; 53(1-3): 39-48.
[http://dx.doi.org/10.1016/S0168-3659(97)00236-8] [PMID: 9741912]
[20]
Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999; 10(2): 289-98.
[http://dx.doi.org/10.1021/bc9801124] [PMID: 10077479]
[21]
Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 2003; 9(17): 6551-9.
[PMID: 14695160]
[22]
Zeisig R, Arndt D, Stahn R, Fichtner I. Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid. Biochim Biophys Acta 1998; 1414(1-2): 238-48.
[http://dx.doi.org/10.1016/S0005-2736(98)00171-0] [PMID: 9804964]
[23]
Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JSW. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 2000; 83(2): 232-8.
[http://dx.doi.org/10.1054/bjoc.1999.1232] [PMID: 10901376]
[24]
Lee CH, Ni YH, Chen CC, Chou CK, Chang FH. Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochim Biophys Acta 2003; 161155: 62.
[25]
Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, Ehrhardt C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006; 29(5): 367-74.
[http://dx.doi.org/10.1016/j.ejps.2006.07.004] [PMID: 16952451]
[26]
Lee CM, Tanaka T, Murai T, et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 2002; 62(15): 4282-8.
[PMID: 12154030]
[27]
Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002; 62(23): 6831-6.
[PMID: 12460895]
[28]
Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 2007; 17(1): 1-14.
[http://dx.doi.org/10.1080/08982100601186474] [PMID: 17454399]
[29]
Chen G, Kumar J, Gregory A, Stenzel MH. Efficient synthesis of dendrimers via a thiol-yne and esterification process and their potential application in the delivery of platinum anti-cancer drugs. Chem Commun (Camb) 2009; 41(41): 6291-3.
[http://dx.doi.org/10.1039/b910340f] [PMID: 19826698]
[30]
Yang W, Cheng Y, Xu T, Wang X, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 2009; 44(2): 862-8.
[http://dx.doi.org/10.1016/j.ejmech.2008.04.021] [PMID: 18550227]
[31]
Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 2011; 31(3): 897-906.
[PMID: 21498711]
[32]
Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al. PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev 2013; 14(11): 6925-8.
[http://dx.doi.org/10.7314/APJCP.2013.14.11.6925] [PMID: 24377627]
[33]
Sato N, Kobayashi H, Saga T, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 2001; 7(11): 3606-12.
[PMID: 11705883]
[34]
Liu Z, Sun X, Nakayama-Ratchford N, Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 2007; 1(1): 50-6.
[http://dx.doi.org/10.1021/nn700040t] [PMID: 19203129]
[35]
Liu X, Huang H, Wang J, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011; 82(1): 17-23.
[http://dx.doi.org/10.1016/j.bcp.2011.03.017] [PMID: 21453684]
[36]
Guo R, Yao Y, Cheng G, et al. Synthesis of glycoconjugated poly(amindoamine) dendrimers for targeting human liver cancer cells. RSC Advances 2012; 2: 99-102.
[http://dx.doi.org/10.1039/C1RA00320H]
[37]
Medina SH, Tekumalla V, Chevliakov MV, Shewach DS, Ensminger WD, El-Sayed MEH. N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 2011; 32(17): 4118-29.
[http://dx.doi.org/10.1016/j.biomaterials.2010.11.068] [PMID: 21429574]
[38]
Radhika R, Rohith V, Kumar ANC, Varun GK, Krishnan NPK, Deepak OM. Insilico analysis of nanopolyamidoamine (PAMAM) dendrimers for cancer drug delivery. IJLTET 2010; 4: 142-4.
[39]
Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012; 63: 185-98.
[http://dx.doi.org/10.1146/annurev-med-040210-162544] [PMID: 21888516]
[40]
Thomas TP, Choi SK, Li MH, Kotlyar A, Baker JR Jr. Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery. Bioorg Med Chem Lett 2010; 20(17): 5191-4.
[http://dx.doi.org/10.1016/j.bmcl.2010.07.005] [PMID: 20659800]
[41]
Bhirde AA, Patel V, Gavard J, et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009; 3(2): 307-16.
[http://dx.doi.org/10.1021/nn800551s] [PMID: 19236065]
[42]
Sinha N, Yeow JT. Carbon nanotubes for biomedical applications. IEEE Trans Nanobioscience 2005; 4(2): 180-95.
[http://dx.doi.org/10.1109/TNB.2005.850478] [PMID: 16117026]
[43]
Zhang X, Meng L, Lu Q, Fei Z, Dyson PJ. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 2009; 30(30): 6041-7.
[http://dx.doi.org/10.1016/j.biomaterials.2009.07.025] [PMID: 19643474]
[44]
Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials 2012; 33(6): 1689-98.
[http://dx.doi.org/10.1016/j.biomaterials.2011.11.004] [PMID: 22137127]
[45]
Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41(1): 60-8.
[http://dx.doi.org/10.1021/ar700089b] [PMID: 17867649]
[46]
Yu Y, Xu L, Chen J, et al. Hydrothermal synthesis of GSH-TGA co-capped CdTe quantum dots and their application in labeling colorectal cancer cells. Colloids Surf B Biointerfaces 2012; 95: 247-53.
[http://dx.doi.org/10.1016/j.colsurfb.2012.03.011] [PMID: 22494668]
[47]
Rusling JF, Sotzing G, Papadimitrakopoulosa F. Designing nanomaterial-enhanced electrochemical immunosensors for cancer biomarker proteins. Bioelectrochemistry 2009; 76(1-2): 189-94.
[http://dx.doi.org/10.1016/j.bioelechem.2009.03.011] [PMID: 19403342]
[48]
Chen J, Chen S, Zhao X, Kuznetsova LV, Wong SS, Ojima I. Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc 2008; 130(49): 16778-85.
[http://dx.doi.org/10.1021/ja805570f] [PMID: 19554734]
[49]
Heister E, Neves V, Carmen T, et al. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon 2009; 47: 2152-60.
[http://dx.doi.org/10.1016/j.carbon.2009.03.057]
[50]
Yang F, Fu L, Long J, Ni QX. Magnetic lymphatic targeting drug delivery system using carbon nanotubes. Med Hypotheses 2008; 70(4): 765-7.
[http://dx.doi.org/10.1016/j.mehy.2007.07.045] [PMID: 17910909]
[51]
Yang F, Hu J, Yang D, et al. Pilot study of targeting magnetic carbon nanotubes to lymph nodes. Nanomedicine (Lond) 2009; 4(3): 317-30.
[http://dx.doi.org/10.2217/nnm.09.5] [PMID: 19331539]
[52]
Li JJ, Yang F, Guo GQ, et al. Preparation of biocompatible multi-walled carbon nanotubes as potential tracers for sentinel lymph node. Polym Int 2010; 59: 169-74.
[53]
Kam NWS, O’Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005; 102(33): 11600-5.
[http://dx.doi.org/10.1073/pnas.0502680102] [PMID: 16087878]
[54]
Li H, Zhang N, Hao Y, et al. Formulation of curcumin delivery with functionalized single-walled carbon nanotubes: characteristics and anticancer effects in vitro. Drug Deliv 2013; 1-9.
[PMID: 24160816]
[55]
Robertson CA, Evans DH, Abrahamse H. Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. JPhotochemPhotobiol B Biol 2009; 96: 1-8.
[56]
Singh RP, Sharma G. Sonali, Singh S, Kumar M, Bajarangprasad L. Pandey, Kochc B, Madaswamy S. Vitamin E TPGS conjugated carbon nanotubes improved efficacy ofdocetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces 2016; 141: 429-42.
[http://dx.doi.org/10.1016/j.colsurfb.2016.02.011] [PMID: 26895505]
[57]
Wang Y, Chen L. Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine (Lond) 2011; 7(4): 385-402.
[http://dx.doi.org/10.1016/j.nano.2010.12.006] [PMID: 21215327]
[58]
Wang C, Wu C, Zhou X, et al. Enhancing cell nucleus accumulation and DNA cleavage activity of anti-cancer drug via graphene quantum dots. Sci Rep 2013; 3: 2852-60.
[http://dx.doi.org/10.1038/srep02852] [PMID: 24092333]
[59]
Nigam P, Waghmode S, Louis M, Wangnoo S, Chavan P, Sarkar D. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. J Mater Chem B Mater Biol Med 2014; 2: 3190-5.
[http://dx.doi.org/10.1039/C4TB00015C]
[60]
Zhang X, Liu M, Liu H, Zhang S. Low-toxic Ag2S quantum dots for photoelectrochemical detection glucose and cancer cells. Biosens Bioelectron 2014; 56: 307-12.
[http://dx.doi.org/10.1016/j.bios.2014.01.033] [PMID: 24525014]
[61]
Wang Y, Yan XP. Fabrication of vascular endothelial growth factor antibody bioconjugated ultrasmall near-infrared fluorescent Ag2S quantum dots for targeted cancer imaging in vivo. Chem Commun (Camb) 2013; 49(32): 3324-6.
[http://dx.doi.org/10.1039/c3cc41141a] [PMID: 23503615]
[62]
Liu L, Yong KT, Roy I, et al. Bioconjugated pluronic triblock-copolymer micelle-encapsulated quantum dots for targeted imaging of cancer: in vitro and in vivo studies. Theranostics 2012; 2(7): 705-13.
[http://dx.doi.org/10.7150/thno.3456] [PMID: 22896772]
[63]
Ruan J, Song H, Qian Q, et al. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. Biomaterials 2012; 33(29): 7093-102.
[http://dx.doi.org/10.1016/j.biomaterials.2012.06.053] [PMID: 22796163]
[64]
Li C, Ji Y, Wang C, et al. BRCAA1 antibody- and Her2 antibody-conjugated amphiphilic polymer engineered CdSe/ZnS quantum dots for targeted imaging of gastric cancer. Nanoscale Res Lett 2014; 9(1): 244-58.
[http://dx.doi.org/10.1186/1556-276X-9-244] [PMID: 24940175]
[65]
Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 2011; 153(1): 16-22.
[http://dx.doi.org/10.1016/j.jconrel.2011.02.015] [PMID: 21342659]
[66]
Chen ML, He YJ, Chen XW, Wang JH. Quantum dots conjugated with Fe3O4-filled carbon nanotubes for cancer-targeted imaging and magnetically guided drug delivery. Langmuir 2012; 28(47): 16469-76.
[http://dx.doi.org/10.1021/la303957y] [PMID: 23131026]
[67]
Erogbogbo F, Tien CA, Chang CW, et al. Bioconjugation of luminescent silicon quantum dots for selective uptake by cancer cells. Bioconjug Chem 2011; 22(6): 1081-8.
[http://dx.doi.org/10.1021/bc100552p] [PMID: 21473652]
[68]
Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012; 9(5): 497-508.
[http://dx.doi.org/10.1517/17425247.2012.673278] [PMID: 22439808]
[69]
Shuhendler AJ, Prasad P, Leung M, Rauth AM, Dacosta RS, Wu XY. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater 2012; 1(5): 600-8.
[http://dx.doi.org/10.1002/adhm.201200006] [PMID: 23184795]
[70]
Shi S, Han L, Deng L, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release 2014; 194: 228-37.
[http://dx.doi.org/10.1016/j.jconrel.2014.09.005] [PMID: 25220161]
[71]
Xu Q, Leong J, Chua QY, et al. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013; 34(21): 5149-62.
[http://dx.doi.org/10.1016/j.biomaterials.2013.03.044] [PMID: 23578555]
[72]
Dai Y, Ma P, Cheng Z, et al. Up-conversion cell imaging and pH-induced thermally controlled drug release from NaYF4/Yb3+/Er3+@hydrogel core-shell hybrid microspheres. ACS Nano 2012; 6(4): 3327-38.
[http://dx.doi.org/10.1021/nn300303q] [PMID: 22435911]
[73]
Lee HY, Mohammed KA, Peruvemba S, Goldberg EP, Nasreen N. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J Pharm Pharmacol 2011; 63(11): 1401-10.
[http://dx.doi.org/10.1111/j.2042-7158.2011.01306.x] [PMID: 21988421]
[74]
Gai S, Yang P, Ma P, et al. Fibrous-structured magnetic and mesoporous Fe3O4/silica microspheres: synthesis and intracellular doxorubicin delivery. J Mater Chem 2011; 21: 16420.
[http://dx.doi.org/10.1039/c1jm13357h]
[75]
Miao J, Du YZ, Yuan H, Zhang XG, Hu FQ. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces 2013; 110: 74-80.
[http://dx.doi.org/10.1016/j.colsurfb.2013.03.037] [PMID: 23711779]
[76]
Delgado D, Gascón AR, Del Pozo-Rodríguez A, et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm 2012; 425(1-2): 35-43.
[http://dx.doi.org/10.1016/j.ijpharm.2011.12.052] [PMID: 22226874]
[77]
Kashanian S, Azandaryani AH, Derakhshandeh K. New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell. Int J Nanomedicine 2011; 6: 2393-401.
[PMID: 22114489]
[78]
Agarwal A, Majumder S, Agrawal H, Majumdar S, Agrawal GP. Cationized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug. Curr Nanosci 2011; 7: 71-80.
[http://dx.doi.org/10.2174/157341311794480291]
[79]
Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 2011; 55(3): 495-503.
[http://dx.doi.org/10.1002/mnfr.201000310] [PMID: 20938993]
[80]
Bhushan S, Kakkar V, Pal HC, et al. Enhanced anticancer potential of encapsulated solid lipid nanoparticles of TPD: a novel triterpenediol from Boswellia serrata. Mol Pharm 2013; 10(1): 225-35.
[http://dx.doi.org/10.1021/mp300385m] [PMID: 23237302]
[81]
Lima AM, Pizzol CD, Monteiro FBF, et al. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J Photochem Photobiol B 2013; 125: 146-54.
[http://dx.doi.org/10.1016/j.jphotobiol.2013.05.010] [PMID: 23816959]
[82]
Martins S, Tho I, Reimold I, et al. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm 2012; 439(1-2): 49-62.
[http://dx.doi.org/10.1016/j.ijpharm.2012.09.054] [PMID: 23046667]
[83]
Jose S, Anju SS, Cinu TA, Aleykutty NA, Thomas S, Souto EB. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int J Pharm 2014; 474(1-2): 6-13.
[http://dx.doi.org/10.1016/j.ijpharm.2014.08.003] [PMID: 25102112]
[84]
Yuba E, Uesugi S, Yoshizaki Y, Harada A, Kono K. Potentiation of cancer immunity-inducing effect by pH-sensitive polysaccharide-modified liposomes with combination of TGF-β type I receptor inhibitor-embedded liposomes. Med Res Arch 2017; 5(5)
[http://dx.doi.org/10.18103/mra.v5i5.1243]
[85]
Yuba E, Osaki T, Ono M, et al. Bleomycin-Loaded pH-Sensitive Polymer−Lipid-Incorporated Liposomes for Cancer Chemotherapy. Polymers (Basel) 2018; 10(1): 74.
[http://dx.doi.org/10.3390/polym10010074] [PMID: 30966109]
[86]
Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv 2018; 25(1): 517-32.
[http://dx.doi.org/10.1080/10717544.2018.1435747] [PMID: 29433357]
[87]
Xia T, He Q, Shi K, et al. Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer. Pharm Dev Technol 2018; 23(1): 13-21.
[http://dx.doi.org/10.1080/10837450.2016.1265553] [PMID: 27884084]
[88]
Steffes VM, Murali MM, Park Y, Fletcher BJ, Ewert KK, Safinya CR. Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies. Biomaterials 2017; 145: 242-55.
[http://dx.doi.org/10.1016/j.biomaterials.2017.08.026] [PMID: 28889081]
[89]
Cai X, Zhu H, Zhang Y, Gu Z. Highly efficient and safe delivery of VEGF siRNA by bioreducible fluorinated peptide dendrimers for cancer therapy. ACS Appl Mater Interfaces 2017; 9(11): 9402-15.
[http://dx.doi.org/10.1021/acsami.6b16689] [PMID: 28228013]
[90]
Zhang Z, Zhou Y, Zhou Z, et al. Synthesis of enzyme-responsive phosphoramidate dendrimers for cancer drug delivery. Polym Chem 2018.
[http://dx.doi.org/10.1039/C7PY01492A]
[91]
Ihnatsyeu-Kachan A, Dzmitruk V, Apartsin E, et al. Multi-target inhibition of cancer cell growth by siRNA cocktails and 5-fluorouracil using effective piperidine-terminated phosphorus dendrimers. Colloids and Interfaces 2017; 1(1): 6.
[http://dx.doi.org/10.3390/colloids1010006]
[92]
Sharma AK, Gupta L, Sahu H, et al. Chitosan engineered pamam dendrimers as nanoconstructs for the enhanced anti-cancer potential and improved in vivo brain pharmacokinetics of temozolomide. Pharm Res 2018; 35(1): 9.
[http://dx.doi.org/10.1007/s11095-017-2324-y] [PMID: 29294212]
[93]
Zhang M, Wang W, Wu F, Yuan P, Chi C, Zhou N. Magnetic and fluorescent carbon nanotubes for dual modal imaging and photothermal and chemo-therapy of cancer cells in living mice. Carbon 2017; 123: 70-83.
[http://dx.doi.org/10.1016/j.carbon.2017.07.032]
[94]
Taghavi S, Nia AH, Abnous K, Ramezani M. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells. Int J Pharm 2017; 516(1-2): 301-12.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.027] [PMID: 27840158]
[95]
Siddiqui MA, Wahab R, Ahmad J, Farshori NN, Musarrat J, Al-Khedhairy AA. Evaluation of cytotoxic responses of raw and functionalized multi-walled carbon nanotubes in human breast cancer (MCF-7) cells. Vacuum 2017; 146: 578-85.
[http://dx.doi.org/10.1016/j.vacuum.2017.05.022]
[96]
Ranjbar-Navazi Z, Eskandani M, Johari-Ahar M, et al. Doxorubicin-conjugated D-glucosamine- and folate- bi-functionalised InP/ZnS quantum dots for cancer cells imaging and therapy. J Drug Target 2018; 26(3): 267-77.
[http://dx.doi.org/10.1080/1061186X.2017.1365876] [PMID: 28795849]
[97]
Tao W, Ji X, Xu X, et al. Antimonene quantum dots: synthesis and application as near‐infrared photothermal agents for effective cancer therapy. Angew Chem Int Ed Engl 2017; 56(39): 11896-900.
[PMID: 28640986]
[98]
Gedda G, Chen GR, Yao YY, et al. Aqueous synthesis of dual-targeting Gd-doped CuInS 2/ZnS quantum dots for cancer-specific bi-modal imaging. New J Chem 2017; 41(23): 14161-70.
[http://dx.doi.org/10.1039/C7NJ02252B]
[99]
Guo X, Chen C, Liu X, et al. High oral bioavailability of 2-methoxyestradiol in PEG-PLGA micelles-microspheres for cancer therapy. Eur J Pharm Biopharm 2017; 117: 116-22.
[http://dx.doi.org/10.1016/j.ejpb.2017.04.003] [PMID: 28396280]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 2
Year: 2020
Page: [149 - 163]
Pages: 15
DOI: 10.2174/2468187309666190823160241

Article Metrics

PDF: 21